摘要
目的 :探讨急性髓系白血病中 Evi1基因表达及意义。方法 :应用 RT- PCR方法检测了 94例急性髓系白血病 (AML ,包括初治 4 9例 ,复发 2 3例 ,缓解 2 2例 )患者及 1 0名正常对照 Evi1基因的表达。结果 :1 0名正常人骨髓单个核细胞中无 Evi1 m RNA的表达。AML 患者 Evi1基因总的阳性表达率为 1 8.1 % (1 7/94 ) ,M5型未见表达 ,其中初治、复发、缓解组的 Evi1基因阳性率分别为2 6 .5 %、1 7.4 %、0 ,初治和复发组差别无显著性 (P=0 .5 5 4 )。M3患者中 Evi1、PML /RARα双阳性组与 PML /RARα单阳性组相比复发率高 (P<0 .0 5 ) ,早期死亡率高。 Evi1阳性的 AML患者多数生存期短。结论 :Evi1基因是一个原癌基因 ,在髓系白血病的发病中起重要作用 ,是髓系白血病预后不良的一个指标。
Objective:To investigate the expression of Evi1 gene in acute myeloid leukemia(AML).Methods:Expression of Evi1 mRNA was detected in HEL leukemia cell lines, 94 AML patients(49 initial treatment , 23 relapse, 22 remission) and 10 healthy subjects by reverse transcriptase polymerase chain reaction (RT PCR).Results:Evi1 mRNA was not detected in 10 healthy subjects , but was expressed in all AML except M5, including 26.5 % in initial treatment, 17.4 % in relapse, 0 in remission. The relapse rate and early mortality rate of M 3 in Evi1 and PML/RARα group was higher than those in PML/RARα group. The survival duration of patients who expressed Evi1 is short.Conclusion:Evi1 gene plays an important role in the pathogenesis of some myeloid malignancies and it is an worse prognostic factor in AML.
出处
《白血病．淋巴瘤》
CAS
2003年第6期346-348,共3页
Journal of Leukemia & Lymphoma
